Patricia Andrews
Director/Board Member at GLYCOMIMETICS, INC.
Net worth: 148 820 $ as of 30/04/2024
Patricia Andrews active positions
| Companies | Position | Start | End |
|---|---|---|---|
| GLYCOMIMETICS, INC. | Director/Board Member | 12/06/2017 | - |
| Independent Dir/Board Member | 12/06/2017 | - | |
| ONCOLYTICS BIOTECH INC. | Director/Board Member | 09/01/2024 | - |
Career history of Patricia Andrews
Former positions of Patricia Andrews
| Companies | Position | Start | End |
|---|---|---|---|
| SUMITOMO PHARMA ONCOLOGY, INC. | Chief Executive Officer | 01/01/2017 | 01/01/2023 |
| INCYTE CORPORATION | Corporate Officer/Principal | 20/10/2008 | 29/08/2012 |
| PFIZER, INC. | Corporate Officer/Principal | 01/10/2008 | 01/10/2008 |
HSBC Bank USA, NA
 HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Corporate Officer/Principal | 01/01/1990 | 01/01/1990 |
| SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | - | - |
Sumitomo Dainippon Pharma Oncology, Inc.
 Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Chief Executive Officer | 01/11/2013 | - |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Director/Board Member | 24/04/2017 | - |
| Chief Executive Officer | 24/04/2017 | - | |
| Corporate Officer/Principal | 14/11/2013 | 24/04/2017 |
Training of Patricia Andrews
| Brown University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Statistics
International
| United States | 10 |
| Japan | 2 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 5 |
| Director/Board Member | 3 |
| Chief Executive Officer | 3 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| Private companies | 4 |
|---|---|
HSBC Bank USA, NA
HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Finance |
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
| SUMITOMO PHARMA ONCOLOGY, INC. |
- Stock Market
- Insiders
- Patricia Andrews
- Experience
